| Ytd | -40.29% | |
| 1y | -23.88% |
| Open | 10.72 | Prev Close | 10.78 | Low | 10.50 | High | 10.75 | Mkt Cap | 746.71M |
| Vol | 7.85K | Avg Vol | 15.68K | EPS | 0.14 | P/E | 75.36 | Forward P/E | 216.49 |
| Beta | 0.09 | Short Ratio | 0.38 | Inst. Own | 0.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-31 | 50-d Avg | 11.78 | 200-d Avg | 14.82 | 1yr Est | 34.35 |
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase